Hot Undervalued Stocks For 2019

&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-928036638&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/928036638/960×0.jpg?fit=scale&q; data-height=&q;645&q; data-width=&q;960&q;&g; Abstract network connection pattern over city skyline

Despite the micro-bubble in &l;a href=&q;https://www.newconstructs.com/bursting-the-micro-bubble-part-1/&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;specific tech stocks&l;/a&g;, investors can still find value in the sector. This tech firm has a long history of profit growth, prudent capital stewardship, and an undervalued stock. It&a;rsquo;s business model creates more value than peers. Add in its position in multiple fast-growing markets and its clear why Insight Enterprises (NSIT) is this week&a;rsquo;s &l;a href=&q;https://www.newconstructs.com/category/stock-plays-of-the-week/&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;Long Idea&l;/a&g;.

Hot Undervalued Stocks For 2019: Great Canadian Gaming Corporation (GCGMF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Clairvest Group previously initiated an investment in a partnership that involved Great Canadian Gaming Corporation (OTCPK:GCGMF) and Brookfield Business Partners LP to operate two casinos in Southern Ontario. With this announcement, we not only get the upside of a 45% ownership of “Ontario Gaming West GLA Limited Partnership,” which includes four major operations, but also 2,500 slot machines, 60 table games, racing track and $450 million in gross gaming revenue. Clairvest has a history in the gambling industry and Great Canadian Gaming Corporation is a proven operator with a terrific track record.

Hot Undervalued Stocks For 2019: Synnex Corporation(SNX)

Advisors’ Opinion:

  • [By Max Byerly]

    Synnex (NYSE: SNX) and Presidio (NASDAQ:PSDO) are both computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

  • [By Ethan Ryder]

    Cross Research lowered shares of SYNNEX (NYSE:SNX) from a buy rating to a hold rating in a report released on Friday morning.

    Other research analysts have also recently issued research reports about the stock. Stifel Nicolaus reduced their price target on shares of SYNNEX from $140.00 to $130.00 and set a buy rating for the company in a report on Friday. Pivotal Research reduced their price target on shares of SYNNEX from $135.00 to $130.00 and set a buy rating for the company in a report on Friday. Needham & Company LLC reiterated a buy rating and issued a $135.00 price target (down previously from $151.00) on shares of SYNNEX in a report on Monday, April 2nd. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of SYNNEX from a sell rating to a hold rating in a report on Tuesday, June 5th. Finally, ValuEngine cut shares of SYNNEX from a hold rating to a sell rating in a report on Wednesday, May 2nd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $141.14.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on SYNNEX (SNX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Undervalued Stocks For 2019: Teva Pharmaceutical Industries Limited(TEVA)

Advisors’ Opinion:

  • [By Chris Lange]

    Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest decreased to 47.70 million from the previous level of 49.03 million. Shares were trading at $23.86, in a 52-week range of $10.85 to $33.82.

  • [By Brian Feroldi, Keith Speights, and Sean Williams]

    As for weaker generic-drug pricing, this isn’t anything new. Generic drugmakers like Teva Pharmaceutical Industries (NYSE:TEVA) have been pressured by weaker generic drug prices since the third quarter of last year. However, weakness in pricing has recently shown signs of stabilizing. Generic drug manufacturers and Wall Street analysts both seem to believe that 2019 will offer much-needed price stabilization for generic therapies. Considering that generics make up the bulk of total written prescription — about nine out of 10 — it seems only logical that pricing power will return to generic drugmakers and distributors sooner rather than later.

  • [By Jon C. Ogg]

    Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) was raised to Outperform from Market Perform with a $22 target price (versus a $17.63 close) at Raymond James.

  • [By Chris Lange]

    24/7 Wall St. had previously reported that Teva Pharmaceutical Ltd. (NYSE: TEVA) is entering the generic EpiPen business, and this could potentially lead to a price war with Mylan.

  • [By Shane Hupp]

    Jafra Capital Management LP purchased a new stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 315,000 shares of the company’s stock, valued at approximately $7,661,000. Teva Pharmaceutical Industries accounts for 2.7% of Jafra Capital Management LP’s portfolio, making the stock its 5th largest position.

  • [By Dan Caplinger]

    Wednesday was a relatively calm day on Wall Street until the last few minutes of the trading session, as major market benchmarks didn’t initially respond in dramatic fashion to much-anticipated news on the interest rate front. As expected, monetary policy from the Federal Reserve remained consistent with the trajectory the central bank has followed for more than a year, and the target on short-term rates climbed by a quarter point to a new range of between 2% and 2.25%. That’s good news for savers, but investors seemed to see mixed implications for companies in different sectors, and a late-day sell-off sent the Dow Jones Industrial Average down more than 100 points. Some stocks also responded negatively to more specific news affecting their businesses. Southwestern Energy (NYSE:SWN), Teva Pharmaceutical Industries (NYSE:TEVA), and Chegg (NYSE:CHGG) were among the worst performers on the day. Here’s why they did so poorly.

Hot Undervalued Stocks For 2019: FS Bancorp, Inc.(FSBW)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on FS Bancorp (FSBW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on FS Bancorp (FSBW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on FS Bancorp (FSBW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Undervalued Stocks For 2019: TransAlta Corporation(TAC)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Shares of TransAlta (TSE:TA) (NYSE:TAC) have been given a consensus rating of “Hold” by the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is C$8.25.

  • [By Max Byerly]

    TransAlta (NYSE: TAC) and CLP (OTCMKTS:CLPHY) are both utilities companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.

  • [By Ethan Ryder]

    TransAlta (NYSE: TAC) and Enel S.p.A. ADS Common Stock (OTCMKTS:ENLAY) are both utilities companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.

Leave a Reply

Your email address will not be published. Required fields are marked *